Positive Two-Year Data Boost Prospects For Vivus' Qnexa
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Two-year Qnexa data released by Vivus Sept. 21 could serve to bolster the long-term prospects for the weight-loss drug as they address areas of concern identified during recent reviews of obesity drugs by FDA's Endocrinologic and Metabolic Drugs Advisory Committee - including higher efficacy standards and the need to show benefit on co-morbidities associated with weight loss
You may also be interested in...
Arena Must Deal With Rat Neoplasms To Move Forward With Lorqess
A major task confronting Arena as it pursues approval of Lorqess is to provide FDA with an explanation that shows the neoplasms found in rats during animal studies of the obesity drug are not a predictor of cancer risk in humans.
FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance
FDA is facing strong pressure from its own advisory committee members to finalize development standards for weight-loss drugs.
Qnexa May Get Staged Launch After No Vote From Advisory Committee
Safety concerns and a large market potential for Vivus's obesity drug combine to produce an advisory panel recommendation that leaves FDA "a little surprised."